Bristol Myers Squibb has become the latest Big Pharma to tie up a biotech pact as we reach the year’s end, tapping Harbour ...

As the FDA steadily churns out a stream of untitled letters chastising pharmaceutical advertisers’ direct-to-consumer ...

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers Squibb ...

Stifel analysts said the label for cardiac myosin inhibitor Myqorzo is in line with their expectations and is differentiated compared with BMS’ Camzyos.

[Editor’s note: The hacker requested that we remove the image for legal reasons, so it’s blurry now. We hope all’s well!] Lithium technology has ushered in a new era of batteries with exceptionally ...

After 27 years in business, Cytokinetics hopes to pit its own cardiac myosin inhibitor against one it initially developed—now owned by Bristol Myers Squibb—in a market worth billions. Aficamten has a ...

Harbour BioMed and Bristol Myers Squibb (BMS) have signed a multi-year, worldwide strategic partnership and licence agreement ...

With FDA approval to treat marginal zone lymphoma (MZL), Bristol Myers Squibb’s Breyanzi has become the first CAR-T therapy in the indication, as well as the first CAR-T to reach the market for five ...

Biopharmaceutical firm Bristol Myers Squibb (BMS) and IT services company Accenture on Wednesday announced the opening of a ...

The latest Fujitsu AIRSTAGE Cloud BMS release, v3.1.4-R4, contains multiple updates and new tools to simplify commissioning ...